ResMed reports Q3 2026 revenue of $1.41 billion and earnings beat
ResMed posted calendar Q3 2026 revenue of $1.41 billion, up 5.9% year‑on‑year, and non‑GAAP earnings per share of $2.91, surpassing analyst estimates by 8.9%. Net income rose 20% to $418.41 million, with GAAP EPS of $2.92, a 23.2% increase. The quarter included the completion of the MatrixCare divestiture and management highlighted product launches, supply‑chain improvements and ongoing input‑cost inflation. The company reaffirmed that inflationary pressure will continue through fiscal 2027.
Why it matters
The earnings beat may support short‑term price appreciation for RMD shares, as investors react to stronger revenue and profit than forecast. Management’s guidance that input‑cost inflation will persist signals margin pressure for the coming year.
Key facts
- 1Revenue was $1.41 billion, up 5.9% YoY. finance.yahoo.com
- 2Adjusted (non‑GAAP) EPS was $2.91, 8.9% above consensus estimates. finance.yahoo.com
- 3Net income increased 20% to $418.41 million. tradingview.com
- 4GAAP EPS was $2.92, a 23.2% rise from the prior quarter. tradingview.com
- 5The MatrixCare divestiture was completed in the quarter. tradingview.com
- 6Management expects input‑cost inflation to continue through fiscal 2027. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.